Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07228689 · ClinicalTrials.gov registry record

AI for Onsite Cytology Evaluation in Endoscopic Ultrasound

A clinical trial of Gastrointestinal Neoplasm and Mass Lesion, sponsored by Orlando Health.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT07228689: Recruiting study of Gastrointestinal Neoplasm and Mass Lesion, sponsored by Orlando Health.

NCT07228689 is a study of Gastrointestinal Neoplasm and Mass Lesion that is actively recruiting participants, run by Orlando Health. The registered enrollment target is 200 participants, above the 66-participant average among 4 other Gastrointestinal Neoplasm trials with a reported enrollment target (203% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07228689, a study of Gastrointestinal Neoplasm and Mass Lesion, is actively recruiting participants, sponsored by Orlando Health.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to determine if the widely available artificial intelligence platform ChatGPT can accurately identify the abnormalities present on cytology specimens obtained at EUS-FNB of solid mass lesions in the gastrointestinal tract, in comparison with interpretation by cytopathologists as the gold standard.

Primary Outcome

The ability of the AI systems to interpret specimen adequacy on cytology images

Interventions

  • DIAGNOSTIC_TEST EUS-guided fine needle biopsy

Study Locations (1)

Florida

  • Orlando Health Digestive Health Institute - Orlando

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-11-12
Est. Completion 2027-10
Orlando Health

21 total trials

What NCT07228689 shows while recruiting

NCT07228689 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 4 other Gastrointestinal Neoplasm trials with a reported enrollment target (203% higher).

The record links to 2 conditions, with Gastrointestinal Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which EUS-guided fine needle biopsy is the first listed.

NCT07228689 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07228689 about?

NCT07228689 is a clinical study titled "AI for Onsite Cytology Evaluation in Endoscopic Ultrasound". The aim of this study is to determine if the widely available artificial intelligence platform ChatGPT can accurately identify the abnormalities present on cytology specimens obtained at EUS-FNB of solid mass lesions in the gastrointestinal tract, in comparison with interpretation by cytopathologist...

What is the current status of trial NCT07228689?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-11-12. Estimated completion is 2027-10.

What conditions does trial NCT07228689 study?

This clinical trial studies the following conditions: Gastrointestinal Neoplasm, Mass Lesion.

What interventions are being tested in trial NCT07228689?

The interventions under investigation include: EUS-guided fine needle biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07228689?

This trial is sponsored by Orlando Health, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07228689 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastrointestinal Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07228689, the US trial registry maintained by the National Library of Medicine. NCT07228689 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.